Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Memphis, Tennessee 38120


The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.


Inclusion Criteria: - Metastatic colorectal cancer, histologically or cytologically confirmed - Age 18 or greater - Adequate hematologic function (ANC > 1500, hemoglobin > 10 g/dl, platelet count > 100,000) - Adequate hepatic parameters (bilirubin < 2.0, Alk. Phos < 5 times normal, ALT < 5 times normal) - Adequate renal function (creatinine < 2.0) - Performance status ECOG 0-2 - 0-2 prior lines of chemotherapy for metastatic colorectal cancer are allowed. Prior 5-FU/LV or capecitabine allowed either in the adjuvant setting, or in the metastatic setting or both. - Absence of other serious concurrent medical illnesses - Evaluable or measurable disease for phase I; measurable disease only for phase II Exclusion Criteria: - Histologies other than adenocarcinoma - Previous grade 4 toxicity to 5-FU +/- LV or capecitabine - Uncontrolled brain metastases - Chronic diarrhea (greater than five bowel movements per day) - Previous chemotherapy or radiation therapy less than 4 weeks prior to study day 1 (less than 6 weeks for chemotherapy with Mitomycin or nitrosoureas) - Major surgery within 2 weeks before study entry - Known allergic sensitivity to leucovorin - Prior exposure to IFN-γ - Previous hematopoietic growth factor (e.g. epoetin alfa or darbepoietin less than 2 weeks prior to study day 1) - Pregnancy or breast feeding. Women of child-bearing potential must have a negative pregnancy test before the first dose. - Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ - Inability to provide written and informed consent - Uncontrolled hypertension - History of deep venous thrombosis or CVA - Prior exposure to bevacizumab - Proteinuria > 500 mg/24 hr



Primary Contact:

Study Chair
Lee Schwartzberg, MD
ACORN Research, LLC

Backup Contact:


Location Contact:

Memphis, Tennessee 38120
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.